Telix's Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
New approval provides hospitals and clinics in the Czech Republic with access to a proven PSMA-PET imaging agent
MELBOURNE, Australia, May 5, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the SÚKL[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval provides healthcare providers in the Czech Republic with broader access to PSMA-PET[3] imaging, using a clinically validated gallium-based radiopharmaceutical.
Illuccix, after radiolabelling with gallium-68, is indicated in the Czech Republic for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings:
Primary staging of patients with high-risk PCa prior to primary curative therapy.
Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy.
Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated.
PSMA-PET imaging represents a significant advance in prostate cancer management, largely replacing conventional imaging methods such as bone scans and CT[4] scans as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines recognize its superior accuracy in staging primary disease and assessing BCR[5]. Illuccix® PSMA-PET will help address an important clinical need by supporting timely and effective diagnosis, as well as identifying patients who may benefit from PSMA-targeted therapy.
Illuccix's broad approval is supported by robust clinical data, including the largest Ga-68-based PSMA data set from the VISION trial[6].
President of the Czech Society of Nuclear Medicine, Dr. David Zogala commented on the approval, 'Waiting for a diagnosis can be a difficult time for men with suspected prostate cancer. In this regard, PSMA-PET imaging has transformed how we assess the disease, offering greater accuracy and confidence in determining its stage, and guiding the correct course of action. The approval of Illuccix will increase access to advanced imaging in the Czech Republic, broadening the portfolio of available PSMA tracers and supporting precise detection and timely decision-making for patients.'
With its broad indication, Illuccix® is designed to support healthcare providers in delivering efficient and reliable imaging. The approval comes as demand for PSMA-PET continues to grow across Europe, reinforcing the need for solutions that fit within existing hospital workflows.
'The Czech Republic has been at the forefront of adopting advanced diagnostics, with Czech nuclear medicine specialists playing a leading role in integrating PSMA-PET imaging into clinical practice. We are pleased to support their efforts by working with THP Medical Products to deliver Illuccix, a clinically validated imaging solution that will help ensure more men benefit from accurate prostate cancer detection and ongoing management.' said Raphaël Ortiz, Chief Executive Officer, Telix International.
Illuccix® will be made available in the Czech Republic through Telix's distribution partner THP Medical Products a specialist supplier and distributor of nuclear medicine products and services. To order or enquire about Illuccix® availability, authorized healthcare professionals in the Czech Republic can email: [email protected] or call +43 1 292 82 80.
Prostate Cancer in the Czech Republic
Prostate cancer is the most common cancer in men in the Czech Republic, with close to 8,000 new cases diagnosed annually, and a significantly higher incidence in men than either bowel (4,376 new cases) or lung cancer (3,709 new cases). Prostate cancer is also the third most common cause of cancer death in men, with over 1,600 men dying from their disease in the Czech Republic in 2022[7].
About Illuccix®
Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[8], by the Australian Therapeutic Goods Administration (TGA)[9], by Health Canada[10], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[11], by the Brazilian Health Regulatory Agency (ANVISA)[12], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[13], and in multiple other European Economic Area (EEA) Member States[14]. Illuccix® is currently in national approval review elsewhere in the EEA following a positive decentralized procedure (DCP) opinion by BfArM[15].
[1] Positron emission tomography.
[2] Státní Ústav Pro Kontrolu Léčiv (State Institute for Drug Control).
[3] Imaging of prostate-specific membrane antigen with positron emission tomography.
[4] Computed tomography.
[5] European Association of Urology (EAU) Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.: https://uroweb.org/guidelines/prostate-cancer; Prostate cancer: European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-genitourinary-cancers/clinical-practice-guidelines-prostate-cancer/eupdate-prostate-cancer-treatment-recommendations
[6] ClinicalTrials.gov ID: NCT03511664. VISION study sponsored by Endocyte, a Novartis company. Telix provided Illuccix® (TLX591-CDx) for PSMA-PET imaging.
[7] Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024.
[8] Telix ASX disclosure 20 December 2021.
[9] Telix ASX disclosure 2 November 2021.
[10] Telix ASX disclosure 14 October 2022.
[11] Telix ASX disclosure 13 February 2025.
[12] Telix ASX disclosure 18 March 2025.
[13] National Agency for the Safety of Medicine and Health Products (Agence nationale de sécurité du médicament et des produits de santé). Telix media release 29 April 2025.
[14] Czech Republic, Denmark, Ireland, Luxembourg, Malta, the Netherlands, Norway and Sweden at time of release.
[15] The German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte). Telix ASX disclosure 17 January 2025.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations
Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: [email protected]
Legal Notices
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.
Logo – https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/telixs-illuccix-psma-pet-imaging-agent-approved-in-the-czech-republic-302445852.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Paul H. Kim Named COO of CJ 4DPLEX, Americas
HOLLYWOOD, Calif., June 11, 2025 /PRNewswire/ — CJ 4DPLEX, the world's leading producer of premium film formats and cinema technologies, today announced the appointment of Paul H. Kim as Chief Operating Officer of CJ 4DPLEX Americas. Kim, a seasoned entertainment executive experienced in content strategy, production and business operations, will oversee daily operations and drive strategic growth for the company's premium cinema formats, SCREENX and 4DX. As COO, Kim will continue to manage and build CJ 4DPLEX's relationships with Hollywood studios, filmmakers and talent while strengthening operational efficiency, and expanding CJ 4DPLEX's footprint in the global entertainment industry. Prior to his appointment as COO, Kim served as Senior Vice President of Content & Production, where under his leadership, SCREENX grew from an emerging format to showcasing a full slate of over 26 Hollywood releases annually. He has negotiated long-term studio agreements that ensured direct investment in the format and spearheaded efforts to introduce the first animated SCREENX films in partnership with Illumination and DreamWorks. Kim has also played a key role in growing the company's in-house VFX capabilities. 'Paul's deep understanding of production, technology and operations, along with his long-standing commitment to CJ 4DPLEX, uniquely qualifies him for this position,' said Don Savant, CEO of CJ 4DPLEX America. 'Throughout his extensive tenure with the company, Paul has been vital in shaping our premium formats and enhancing our presence and relationships in Hollywood. His dedication and leadership will be essential as we continue to grow and innovate in the cinematic space.' 'I am honored to take on this new role at CJ 4DPLEX, Americas and continue driving the company's vision of redefining the cinematic experience,' said Kim. 'With the growing demand for premium formats, I look forward to working more closely with our studio partners, creative teams, and exhibitors to bring audiences even more unforgettable moviegoing experiences.' In 2011, Kim began his career at CJ4DPLEX's parent company CJ Group, which also includes entertainment powerhouses CJ CGV, the fifth largest theater chain in the world, and CJ ENM (CJ Entertainment & Media), who produced the Academy Award®-winning film, 'Parasite.' Kim played a foundational role in the development of SCREENX in 2012, helping take the format from an early concept to full commercialization. SCREENX, which showcases a 270-degree panoramic viewing experience, is now featured in over 425 locations worldwide. Kim's move to Los Angeles in 2015 marked a pivotal shift in expanding CJ 4DPLEX's presence in Hollywood, helping strengthen its relationships with major studios and secure the company's position in the industry. Kim's promotion marks a new chapter for CJ 4DPLEX as the company continues to push the boundaries of cinematic storytelling. With a focus on innovation and strategic expansion, CJ 4DPLEX is poised for continued growth in the global entertainment landscape. About CJ 4DPLEXCJ 4DPLEX is a leading, next-generation cinema technology company, headquartered in Seoul with international offices in Los Angeles, Beijing, and London. The company has created innovative film technologies for theaters worldwide that include 'SCREENX', '4DX', and 'Ultra 4DX' for consumers to experience films in ways that were never before possible. CJ 4DPLEX is a part of the CJ Group conglomerate that also includes entertainment powerhouses CJ CGV, the fifth largest theater chain in the world, and CJ ENM (CJ Entertainment & Media), who produced the Academy Award®, Golden Globe® and SAG Awards winning film, 'Parasite'. SCREENX is the world's first multi-projection cinema with an immersive 270 degree field of view. By expanding the image beyond the frame and onto the walls of the theater, SCREENX places the audience directly at the center of the story, creating a visually immersive viewing experience unlike any other. To date, there are over 435 SCREENX auditoriums around the world in 40 countries. 4DX provides moviegoers with a multi-sensory cinema-going experience, allowing audiences to connect with movies through motion, vibration, water, wind, snow, lightning, scents, and other special effects that enhance the visuals on-screen. Each 4DX auditorium incorporates motion-based seating synchronized with more than 21 different effects and optimized by a team of skilled editors. To date, there are over 775 4DX auditoriums around the world, spanning over 70 countries.
Malaysian Reserve
4 hours ago
- Malaysian Reserve
United States Presidential Culinary Museum® Celebrates America 250 with Launch of "The Washington's Famous Syllabub Drink"
GROVER, N.C., June 11, 2025 /PRNewswire/ — In honor of the Semiquincentennial—America's 250th anniversary of independence—the United States Presidential Culinary Museum® is continuing to promote the national celebration with a unique culinary tribute: the Founding Families Syllabub, a fun, free-wheeling drink of the beloved Colonial-era libations. America's 250th anniversary is officially being marked by a year‑long series of national events, beginning Memorial Day 2025 and rocketing into July 4, 2026. With events spanning the federal government, local institutions, nonprofits, and the public, this multi-faceted celebration is meant to rekindle our country's rich history and spirit. Syllabub, a frothy, sweet drink traditionally made with cream, sugar, and wine or brandy, has a storied past dating back to the 1500s during the reign of the Tudors starting with King Henry VII, son of Edmund Tudor, 1st Earl of Richmond, and Lady Margaret Beaufort. It remained a favorite for more than 300 years. Long before eggnog with a dash of cinnamon became the seasonal staple, Syllabub was enjoyed year-round—both in England and in the American colonies. The drink's popularity grew immensely in the 1700s, despite sugar being heavily taxed and politically controversial for British colonists. In America, even amidst this taxation tension, Syllabub became a fashionable indulgence. By the time of the American Revolution, it had become a signature at social gatherings, particularly among Founding Fathers and First Lady Dolley Madison, who famously served it at White House receptions. Syllabub wasn't just a drink—it was an experience. It had its own glassware, utensils, and preparation techniques designed to create the perfect whipped froth on top. Initially served in clay mugs, its visual appeal led to the development of clear glass vessels, which triggered a consumer revolution of insanity purchasing. Middle-class households began purchasing specialty Syllabub sets, and merchants advertised entire fancy collections in their shops. During the Revolutionary War, the drink remained popular—even when fancy glassware was hard to come by. Colonists, considering themselves British Americans, were keen to keep pace with fashion trends from the U.K.—from food and drink to décor and dress. Owning Syllabub glassware was as much about identity as it was about indulgence. Today, the United States Presidential Culinary Museum® is proud to revive this historic beverage with an authentic, verified recipe from George and Martha Washington. Syllabub was famously served at the W Mount Vernon estate, Jefferson's Monticello, the Madison's Montpelier, according to historical records and is featured there today as well as at Williamsburg, The American Revolutionary War Living History Center, and Old Salem Village. Event Highlights: – Launch reception on July 4, 2025, at 3:00 PM in the Museum's Presidential Dining Room – Syllabub tasting stations, menu pairings, and live culinary demonstrations including non-alcoholic versions and how to create those – Historical talk series, 'Sips from the Past: Colonial Drinks & Diplomacy' streamed on the PRESENTS™ Network via YouTube, Linkedin LIVE, Instagram, TWITCH, and Facebook Former White House Master Chef Marti Mongiello with his wife, Executive Chef Stormy Mongiello, Museum President, and Tournant Chef Barry Mongiello note: 'Food—and drink—tell stories. Our syllabub bridges gastronomy and history, letting people taste, touch, and smell the touch of Colonial America. We're proud to be part of the nation's 250th celebrations.' About the United States Presidential Culinary Museum® Located in Grover, NC., the town celebrates being named after President Grover Cleveland and is in Cleveland County, NC. It's dedicated to preserving and sharing the culinary traditions of America's presidents, first ladies, and their families. Through exhibitions, TV appearances, keynote speeches, White House replica luncheons and dinners, recipes, and tastings, it explores how food and drink reflect cultural and historical moments. Marti and Stormy Mongiello serve as the leading chefs, and both are disabled veterans of 36 years combined military service. Media Contact:Master Chef Marti Mongiello, MBA, MA, MCFEThe United States Presidential Culinary Museum® The US Presidential Service Center®301 Cleveland Ave, Grover, NC 28073 and (704) 937-2940ceo@ Historic Recipe: Washington Family Syllabub From the Kitchen of President George and Martha Washington. Perfected by Executive Chef to the Washington's, Hercules Posey – who later ran away from being a slave. Ingredients:– 1 Quart of heavy cream – 1 Cup of white wine– 6 Tablespoons white sugar – 1 whole nutmeg (grated) or ground nutmeg– 2 Tablespoons of rose water (can be bought or made with hot water and rose petals)– Zest of 1/2 lemon– Sprig of Rosemary– Salt (a pinch) Instructions from the manuscripts given by Franics Parke Custis to Martha Washington: Scald the cream together with the nutmeg, cut in quarters. Remove from the fire and when cool, pour in a glass jar. Let stand overnight. Mix the white wine, rose water, sugar, and a pinch of salt. Pour the cream over this and lay in the rosemary and lemon peel. Let stand for five or six hours until the curds form. The modern method: Pour cream into a bowl and beat with a whisk or electric mixer until soft peaks appear. Add the sugar, lemon zest, salt, rose water, nutmeg and beat briefly. Pour in the wine (experiment with sweet or dry wines, etc.) and mix then put into glasses and place into the refrigerator overnight to separate into cool layers. Decorate with more lemon zest and the sprigs of Rosemary. All types of other decorations can be fantasized about and made as well as adding even more whipped cream on top with grated nutmeg. Traditionally served in Syllabub glasses to show off the distinct layers, this recipe was a favorite of all of the revolutionary founding families and frequently offered at elegant affairs at the White House, private first family estates, on Presidential yachts and rail cars, and at the Camp David Resort and Conference Center. A 'Whipt Syllabub' of the era would include many different flavor ideas of lemon and strawberry and other ideas and also could be made with egg whites and heavy cream mixed with sugar and wine beaten to a froth.
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Instructure's Canvas LMS Enters South Korea to Strengthen Universities' Global Competitiveness
SEOUL, South Korea, June 12, 2025 /PRNewswire/ — Instructure, the leading learning ecosystem and creator of Canvas, one of the most used learning management systems worldwide, today announced its entry into the South Korean market. This expansion marks a significant milestone in the company's mission to empower educators and learners worldwide with a secure, scalable, and modern learning management system. The launch in South Korea is made possible through a strategic partnership with Linus, the authorized partner of Canvas in the country, with over 10 years of experience in the Korean education market. Through this collaboration, educational institutions across the country will gain access to Canvas' full suite of tools and services through locally based employees, localized marketing presence, and enhanced language capability. 'With Canvas LMS, learners in South Korea will gain access to world-class, student-centered learning experiences that unlock personalized and self-paced education,' said Harrison Kelly, Managing Director of Asia Pacific at Instructure. 'More importantly, Canvas by Instructure empowers institutions to bridge the gap between academic theory and real-world application, helping them deliver job-aligned content and credentials that prepare students for a rapidly evolving workforce. We're excited to bring all the fully featured LMS capabilities built in Canvas by Instructure to institutions in the country, supported by Linus's local expertise.' Built to Scale, Secure by Design Unlike open-source LMS platforms that often rely on custom development and ongoing maintenance, Canvas by Instructure is engineered with a secure, enterprise-grade architecture that ensures long-term agility. With 99.9% annual uptime and hands-free updates, institutions can scale confidently while minimizing operational risks. Open Architecture for Seamless Integration Canvas is designed for extensibility. Through robust APIs and full support for Learning Tools Interoperability (LTI) standards, it integrates effortlessly with leading edtech tools, enabling institutions to build flexible, personalized learning ecosystems. Reliability, Resilience, and Risk Management Canvas provides built-in business continuity features, including automatic updates, disaster recovery, vulnerability patching, and rigorous security protocols—all of which support a reliable and safe learning experience for students and faculty alike. AI That Empowers Educators Canvas is also at the forefront of AI innovation in education. With AI-powered tools that support learner engagement and predictive analytics to help identify at-risk students, Canvas enables educators to personalize learning at scale and enhance student outcomes. 'It is a great honor for Linus to become Instructure's first authorized partner in Korea,' said Nah Suk Gyu, CEO of Linus. 'Through this strong partnership with Instructure, a global leader in education technology, we are now able to contribute to enhancing the global competitiveness of Korean educational institutions with the world-class Canvas LMS.' About Instructure Instructure powers the delivery of education globally and reimagines the technologies that turn teaching and learning into opportunities. Today, the Instructure ecosystem of products connects the dots for educators and institutions by improving educational experiences at every age, every stage and every transitional moment — across K-12, higher education and the workforce. We encourage you to discover more at Logo – View original content:
